Ruth M Ruprecht1, Samir K Lakhashe. 1. aDepartment of Virology & Immunology, Texas Biomedical Research Institute bSouthwest National Primate Research Center, San Antonio, Texas, USA.
Abstract
PURPOSE OF REVIEW: Although approximately 90% of all HIV transmissions in humans occur through mucosal contact, the induction of mucosal anti-HIV immune responses has remained understudied. Here we summarize data demonstrating the powerful protection that is achievable at mucosal frontlines through virus-specific mucosal IgA alone or combined with IgG. RECENT FINDINGS: Passive immunization with different monoclonal antibody subclasses but identical epitope specificity (the conserved V3-loop crown of HIV gp120) has revealed that the dimeric IgA1 (dIgA1) form with its open hinge can prevent simian-human immunodeficiency virus (SHIV) acquisition in rhesus macaques at a higher rate than dIgA2. Both dIgAs neutralized the challenge SHIV equally well. Protection was linked to better virion capture and inhibition of cell-free virus transcytosis by dIgA1. Synergistic interactions at the mucosal level between the IgG1 and dIgA2 versions of this monoclonal antibody yielded complete protection. Active vaccine strategies designed to induce mucosal IgA and systemic/mucosal IgG have given promising data. SUMMARY: This review seeks to highlight the importance of mucosal IgAs in preventing virus acquisition. Passive immunization gave proof-of-concept for immune exclusion by mucosally administered monoclonal dIgAs. Unanswered questions remain regarding the interplay between mucosal IgA and other host immune defenses, including their induction with active immunization.
PURPOSE OF REVIEW: Although approximately 90% of all HIV transmissions in humans occur through mucosal contact, the induction of mucosal anti-HIV immune responses has remained understudied. Here we summarize data demonstrating the powerful protection that is achievable at mucosal frontlines through virus-specific mucosal IgA alone or combined with IgG. RECENT FINDINGS: Passive immunization with different monoclonal antibody subclasses but identical epitope specificity (the conserved V3-loop crown of HIV gp120) has revealed that the dimeric IgA1 (dIgA1) form with its open hinge can prevent simian-human immunodeficiency virus (SHIV) acquisition in rhesus macaques at a higher rate than dIgA2. Both dIgAs neutralized the challenge SHIV equally well. Protection was linked to better virion capture and inhibition of cell-free virus transcytosis by dIgA1. Synergistic interactions at the mucosal level between the IgG1 and dIgA2 versions of this monoclonal antibody yielded complete protection. Active vaccine strategies designed to induce mucosal IgA and systemic/mucosal IgG have given promising data. SUMMARY: This review seeks to highlight the importance of mucosal IgAs in preventing virus acquisition. Passive immunization gave proof-of-concept for immune exclusion by mucosally administered monoclonal dIgAs. Unanswered questions remain regarding the interplay between mucosal IgA and other host immune defenses, including their induction with active immunization.
Authors: Alexandra Bonner; Adel Almogren; Patricia B Furtado; Michael A Kerr; Stephen J Perkins Journal: J Biol Chem Date: 2008-12-23 Impact factor: 5.157
Authors: Alexandra Bonner; Patricia B Furtado; Adel Almogren; Michael A Kerr; Stephen J Perkins Journal: J Immunol Date: 2008-01-15 Impact factor: 5.422
Authors: María Julia Ruiz; Yanina Ghiglione; Juliana Falivene; Natalia Laufer; María Pía Holgado; María Eugenia Socías; Pedro Cahn; Omar Sued; Luis Giavedoni; Horacio Salomón; María Magdalena Gherardi; Ana María Rodríguez; Gabriela Turk Journal: J Virol Date: 2016-01-15 Impact factor: 5.103
Authors: Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury Journal: NPJ Vaccines Date: 2020-05-18 Impact factor: 7.344
Authors: Jeffrey R Schneider; Xiaoying Shen; Chiara Orlandi; Tinashe Nyanhete; Sheetal Sawant; Ann M Carias; Archer D Smith; Neil L Kelleher; Ronald S Veazey; George K Lewis; Georgia D Tomaras; Thomas J Hope Journal: J Virol Date: 2020-02-14 Impact factor: 5.103
Authors: Siqi Gong; Khamis Tomusange; Viraj Kulkarni; Opeyemi S Adeniji; Samir K Lakhashe; Dinesh Hariraju; Amanda Strickland; Elizabeth Plake; Patrice A Frost; Sarah J Ratcliffe; Liping Wang; Eileen M Lafer; Ruth M Ruprecht Journal: AIDS Date: 2018-07-17 Impact factor: 4.177
Authors: Hongzhao Li; Yan Hai; So-Yon Lim; Nikki Toledo; Jose Crecente-Campo; Dane Schalk; Lin Li; Robert W Omange; Tamara G Dacoba; Lewis R Liu; Mohammad Abul Kashem; Yanmin Wan; Binhua Liang; Qingsheng Li; Eva Rakasz; Nancy Schultz-Darken; Maria J Alonso; Francis A Plummer; James B Whitney; Ma Luo Journal: PLoS One Date: 2018-08-28 Impact factor: 3.240
Authors: Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury Journal: NPJ Vaccines Date: 2020-05-18 Impact factor: 7.344